Saltar al contenido
Merck

Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis.

Rheumatic diseases clinics of North America (1998-08-26)
J R O'Dell
RESUMEN

Combinations of DMARDs are currently used to treat rheumatoid arthritis by almost all rheumatologists. This article reviews the published data on the triple combination of methotrexate, sulfasalazine, and hydroxychloroquine, discusses caveats for clinical use, compares efficacy of different combinations, and speculates on future combination therapies.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Sulfasalazine, 97.0-101.5%